Imidazopyridin-2-one derivatives as inhibitors of endothelial lipaseThe present invention relates to imidazopyridin-2-one derivatives of the formula (I) with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments. The compounds are inhibitors of endothelial lipase.Compatible salt on the tautomeric form of formula i compound, this compound and the physiology thereof,wherein:x is identical or differently=c (r)-or=n-, wherein at least one x and at the most two x be=n-;w is-(c=o)-,-(s=o)-,-(so 2)-; r is hydrogen, halogen, (c identical or differently 1-c 6)-alkyl, (c 1-c 3)-haloalkyl, (c 1-c 3)-alkoxyl group-(c 1-c 3)-alkylidene group, aryl, heterocycle, hydroxyl, (c 1-c 6)-alkoxyl group, (c 1-c 3)-halogenated alkoxy, aryloxy, cyano group, nitro ,-s (o) p-(c 1-c 6)-alkyl, p=0,1 or 2 wherein, amino-sulfonyl, five fluorine sulfenyls, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, (c 1-c 6)-alkyl-carbonyl, coor3, co-nr4r5, o-co-nr4r5, o-co-(c 1-c 6)-alkylidene group-co-o-(c 1-c 6)-alkyl, o-co-(c 1-c 6)-alkylidene group-co-oh, o-co-(c 1-c 6)-alkylidene group-co-nr4r5; r1, the r1 ' (c that identical or differently respectively does for oneself 5-c 16)-alkyl, (c 5-c 12)-cycloalkyl, (c 1-c 4)-alkylidene aryl, (c 1-c 4)-alkylidene group heteroaryl, (c 1-c 4)-alkylidene group-(c 5-c 12)-cycloalkyl, two rings, wherein aryl, heteroaryl, cycloalkyl or two rings can be by following preferred group lists-or polysubstituted: halogen, (c 1-c 6)-alkyl, (c 1-c 6)-alkoxyl group, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, list-(c 1-c 6)-alkyl amino-carbonyl, two-(c 2-c 8)-alkyl amino-carbonyl, (c 1-c 6)-alkoxy carbonyl, (c 1-c 6)-alkyl-carbonyl, cyano group, nitro, trifluoromethyl, trifluoromethoxy, five fluorine sulfenyls, (c 1-c 6)-alkyl sulphonyl, amino-sulfonyl; r1 ' is (c 1-c 16)-alkyl, (c 5-c 12)-cycloalkyl, (c 1-c 4)-alkylidene aryl, (c 1-c 4)-alkylidene group heteroaryl, (c 1-c 4)-alkylidene group-(c 5-c 12)-cycloalkyl, two rings, wherein aryl, heteroaryl, cycloalkyl or two rings can be by following preferred group lists-or polysubstituted: halogen, (c 1-c 6)-alkyl, (c 1-c 6)-alkoxyl group, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, list-(c 1-c 6)-alkyl amino-carbonyl, two-(c 2-c 8)-alkyl amino-carbonyl, (c 1-c 6)-alkoxy carbonyl, (c 1-c 6)-alkyl-carbonyl, cyano group, nitro, trifluoromethyl, trifluoromethoxy, (c 1-c 6)-alkyl sulphonyl, amino-sulfonyl; r2 is a hydrogen;r3 is hydrogen, (c identical or differently 1-c 6)-alkyl, benzyl; the identical or different ground of r4, r5 each hydrogen, (c naturally 1-c 6)-alkyl, aryl, (c 3-c 12)-cycloalkyl, (c 1-c 4)-alkylidene aryl, (c 1-c 3)-alkylidene group-(c 3-c 12)-cycloalkyl; r6 is hydrogen, (c 1-c 10)-alkyl, (c 1-c 4)-alkylidene aryl, (c 1-c 4)-alkylidenyl-heterocyclic, (c 1-c 4)-alkylidene group-(c 3-c 12)-cycloalkyl, two rings, wherein aryl, heterocycle, cycloalkyl or two rings can be by following preferred group lists-or polysubstituted: halogen, (c 1-c 6)-alkyl, (c 1-c 6)-alkoxyl group, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, list-(c 1-c 6)-alkyl amino-carbonyl, two-(c 2-c 8)-alkyl amino-carbonyl, (c 1-c 6)-alkoxy carbonyl, (c 1-c 6)-alkyl-carbonyl, trifluoromethyl, trifluoromethoxy, cyano group, (c 1-c 6)-alkyl sulphonyl, amino-sulfonyl; or-(c＝o)-nr1′r2；or-(c＝o)-o-r1″；condition be when r1 be (c 5-c 16during)-alkyl, r6 is not (c 1-c 4)-alkylidene aryl, (c 1-c 4)-alkylidenyl-heterocyclic, (c 1-c 4)-alkylidene group-(c 3-c 12)-cycloalkyl or two rings.
내피 리파제의 억제제로서의 이미다조피리딘-2-온 유도체본 발명은 본원에 특정하게 정의된 바와 같은 화학식 I의 이미다조피리딘-2-온 유도체, 이의 약제학적으로 사용가능한 염 및 약제로서의 이의 용도에 관한 것이다. 당해 화합물은 내피 리파제의 억제제이다. 화학식 I  화학식 I의 화합물, 상기 화합물의 토오토머 형태 및 생리학적으로 허용되는 이의 염. 화학식 I [이미지] 상기 화학식 I에서, X는 동일하거나 상이하고, =C(-R)- 또는 =N-이며, 여기서 1 또는 2개의 X는 =N-이고, W는 -(C=O)-, -(S=O)- 또는 -(SO2)-이고, R은 동일하거나 상이하고, 수소, 할로겐, (C1-C6)-알킬, (C1-C3)-할로알킬, (C1-C3)-알킬옥시-(C1-C3)-알킬렌, 아릴, 헤테로사이클, 하이드록실, (C1-C6)-알킬옥시, (C1-C3)-할로알킬옥시, 아릴옥시, 시아노, 니트로, -S(O)p-(C1-C6)-알킬(여기서, p는 0, 1 또는 2이다), 아미노설포닐, 펜타플루오로설파닐, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, (C1-C6)-알킬카보닐, COOR3, CO-NR4R5, O-CO-NR4R5, O-CO-(C1-C6)-알킬렌-CO-O-(C1-C6)-알킬, O-CO-(C1-C6)-알킬렌-CO-OH 또는 O-CO-(C1-C6)-알킬렌-CO-NR4R5이고, R1 및 R1'은 동일하거나 상이하고, 각각 (C5-C16)-알킬, (C5-C12)-사이클로알킬, (C1-C4)-알킬렌아릴, (C1-C4)-알킬렌헤테로아릴, (C1-C4)-알킬렌-(C5-C12)-사이클로알킬 또는 비사이클이고, 여기서 상기 아릴, 헤테로아릴, 사이클로알킬 또는 비사이클은 바람직하게는 할로겐, (C1-C6)-알킬, (C1-C6)-알킬옥시, 하이드록실, (C1-C6)-알킬머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, 모노-(C1-C6)-알킬아미노카보닐, 디-(C2-C8)-알킬아미노카보닐, (C1-C6)-알킬옥시카보닐, (C1-C6)-알킬카보닐, 시아노, 니트로, 트리플루오로메틸, 트리플루오로메틸옥시, 펜타플루오로설파닐, (C1-C6)-알킬설포닐 또는 아미노설포닐로 1회 이상 치환될 수 있고, R1"은 (C1-C16)-알킬, (C5-C12)-사이클로알킬, (C1-C4)-알킬렌아릴, (C1-C4)-알킬렌헤테로아릴, (C1-C4)-알킬렌-(C5-C12)-사이클로알킬 또는 비사이클이고, 여기서 상기 아릴, 헤테로아릴, 사이클로알킬 또는 비사이클은 바람직하게는 할로겐, (C1-C6)-알킬, (C1-C6)-알킬옥시, 하이드록실, (C1-C6)-알킬머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, 모노-(C1-C6)-알킬아미노카보닐, 디-(C2-C8)-알킬아미노카보닐, (C1-C6)-알킬옥시카보닐, (C1-C6)-알킬카보닐, 시아노, 니트로, 트리플루오로메틸, 트리플루오로메틸옥시, (C1-C6)-알킬설포닐 또는 아미노설포닐로 1회 이상 치환될 수 있고, R2는 수소이고, R3은 동일하거나 상이하고, 수소, (C1-C6)-알킬 또는 벤질이고, R4 및 R5는 동일하거나 상이하고, 각각은 수소, (C1-C6)-알킬, 아릴, (C3-C12)-사이클로알킬, (C1-C4)-알킬렌아릴 또는 (C1-C3)-알킬렌-(C3-C12)-사이클로알킬이고, R6은 수소, (C1-C10)-알킬, (C1-C4)-알킬렌아릴, (C1-C4)-알킬렌-헤테로사이클, (C1-C4)-알킬렌-(C3-C12)-사이클로알킬 또는 비사이클(여기서 상기 아릴, 헤테로사이클, 사이클로알킬 또는 비사이클은 바람직하게는 할로겐, (C1-C6)-알킬, (C1-C6)-알킬옥시, 하이드록시, (C1-C6)-알킬머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, 모노-(C1-C6)-알킬아미노카보닐, 디-(C2-C8)-알킬아미노카보닐, (C1-C6)-알콕시카보닐, (C1-C6)-알킬카보닐, 트리플루오로메틸, 트리플루오로메틸옥시, 시아노, (C1-C6)-알킬설포닐 또는 아미노설포닐로 1회 이상 치환될 수 있다)이거나, -(C=O)-NR1'R2 또는 -(C=O)-O-R1"이고, 단, R1이 (C5-C16)-알킬인 경우, R6은 (C1-C4)-알킬렌아릴, (C1-C4)-알킬렌-헤테로사이클, (C1-C4)-알킬렌-(C3-C12)-사이클로알킬 또는 비사이클이 아니다. 